RE:RE:RE:Silver liningFooled again by this company.
Forget the 4-7 x dose. In ligth of the actual situation, this is very unlikely. And again, the 10% of free docetaxel they claim, we don't know what it is. With the toxicity we see, it is likely that it is more than 10% of the dose injected. Also, I never like docetaxel as a warhead, not powerful enoufgh and too much resistance to it in advanced patient. Also, we pay for the non testing of patients for sortilin overexpression as a criteria for enrollment. We are so far from proof of concept, and again, the company decided to not release any data that would allow me to think the problem is dosing. Again, they inject only 30% more than the MTD of docetaxel alone. So the toxicity problem raise doubts about the validity of TH1902 entering cells expressing sortilin in humans. Also, when they will restart the trial, it will be hard to enroll patients. With what we know now, would you be willing to enroll in this trial? We understand now why enrollment was so sluggish.
Wino115 wrote:
They have room to play with dosage levels given it concentrates the normal dose 4-7x, so theoretically you could cut the dose in half and go more frequently and still deliver 2-4x the normal dose and that could go a long way toward eliminating side effects but getting the chemo directly in. In hindsight, it probably would have been worth trialing a large dose at 3 weeks and a half dose at 8 days and see which gives you better parameters. That's essentially what they're planning on doing now.